SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (5983)4/11/2002 12:00:00 PM
From: aknahow  Read Replies (1) of 52153
 
Learning from the past or about to make a new mistake? The PDLI psoriasis trial results were easy to figure out by analyst that spoke to doctors involved in the trial, before unblinding. Even I understood why.

Does AVAN present a similar situation? Good HDL levels will be measured. Trial probably had fast enrollment. Six month booster shots probably already given to many trial participants and while HDL levels probably measured frequently they would IMO certainly have been measured prior to the booster. Even while blinded the results of HDL measurement would provide good clue to value of the vaccine. No real reason for placebo group HDL to increase.


From 10K for 2001

These data were extremely helpful in moving the program forward to a placebo controlled Phase II study, which was initiated in August 2001, in approximately 200 patients
with low levels of HDL cholesterol. The objectives of the study are to evaluate the safety, immunogenicity and dose-response relationship of the CETi-1 product in patients who
receive an initial immunization followed by boosters. The primary endpoint is the change in HDL cholesterol measured after the six-month booster and results are expected from the
trial during 2003. As clinical data become available, we plan to seek a corporate partner to complete development and to commercialize the CETi-1 vaccine.

Disclosure. Own a very small dollar amount of AVAN. Interest mainly because PDLI situation made me realize results of some very few trials could be obvious prior to unblinding, and AVAN moving up sharply around time of booster shots.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News